跳至主要内容
临床试验/NCT03483792
NCT03483792已完成不适用

Heritability of Polycystic Ovary Syndrome: Role of Antimullerian Hormone, Steroids and Leptin

University Hospital, Lille1 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2018年4月20日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
58
试验地点
1
主要终点
Rate of plasma AMH in the 3rd trimester of pregnancy

研究概览

简要总结

Polycystic ovary syndrome (PCOS) is the most common cause of ovulation disorders and affects 10 to 15% of women. Despite its frequency, its physiopathology remains unknown.

In women, Anti-Müllerian hormone (AMH) is secreted by granulosa cells located in the ovaries within the follicles. Compared to control women, serum AMH level is higher in PCOS women and could play a role in its pathophysiology. The severity of the PCOS phenotype is correlated with the production of AMH.

It is currently described in the literature that daughters of women with PCOS have a 50% risk of developing PCOS, but no genetic cause of transmission is known. In mice (article in press), pregnant females injected with AMH give birth to offspring with PCOS symptoms. The AMH could thus also play a role in the heritability of PCOS in women. Our team demonstrated that AMH, in its active cleaved form, had a direct central action on the hypothalamus by increasing the pulsatility of GnRH, inducing LH hypersecretion. The hypothesis is that AMH remains higher in pregnant women with PCOS and may affect the fetus by altering fetal and maternal hypothalamic secretions or by modifying placental steroid production.

Leptin has a role in reproduction, through its receptors located at the central (hypothalamus) and peripheral (granulosa cells) levels. In excessively high serum concentration, as observed in obesity, it would lead to a dysregulation of GnRH secretion, an alteration of ovarian steroidogenesis and a dysregulation of folliculogenesis.

Will be compare leptin levels in first trimester patients with and without PCOS to look for possible correlations between AMH and leptin and eliminate possible bias.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 43 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Having a pre-conceptional infertility assessment in the gynecology-Endocrinology department of University Hospital of Lille
  • in the first trimester of mono fetal pregnancy (between 5 and 10 weeks of gestation), obtained spontaneously, after induction of ovulation or Assisted Reproductive Techniques (ART)
  • Pregnancy followed at University Hospital of Lille
  • PCOS group: defined according to modified Rotterdam criteria (2003 and 2011)
  • At least 2 of the following 3 criterion:
  • Cycle disorder
  • Clinical and / or biological hyperandrogenism
  • Ovarian volume > 10cm³ and/or more than 19 follicles from 2 to 9 mm per ovary
  • After exclusion of other causes of cycle disorder or hyperandrogenism
  • Control group: patient with severe male and / or tubal infertility, no cycling disorder, normal ovarian reserve (FSH<10 IU / L, E2<50 pg / ml, AMH>7 and <35 pmol / L and Follicles count between >5 and <20 per ovary at day 3 of the cycle).
  • In the group of female controls, the fertility problem is not related to a female pathology of the hypothalamic-pituitary-ovarian axis (tubal or male infertility). They are women without ovarian personal pathology. The problem of fertility being of other origin.

排除标准

  • Multiple pregnancy
  • Pregnancy after egg donation
  • Long-term drug therapy (excluding routine pregnancy supplementation)
  • Previous Diabetes
  • Bariatric surgery
  • Patients with ovulatory infertility of central or idiopathic origin
  • Patients already included in another protocol

研究组 & 干预措施

PCOS group

干预措施: Plasma dosage (Biological)

PCOS group

干预措施: placental biopsy (Genetic)

Control group

干预措施: Plasma dosage (Biological)

Control group

干预措施: placental biopsy (Genetic)

结局指标

主要结局

Rate of plasma AMH in the 3rd trimester of pregnancy

时间窗: between 29 and 44 amenorrhea weeks

次要结局

  • The variation of maternal plasma AMH(At baseline, between 5 and 15 amenorrhea weeks, between 15+1 day and 28+ 6 days amenorrhea weeks, between 29 and 44 amenorrhea weeks)
  • The percentage change in the different forms of AMH (pro-AMH and cleaved forms)(At baseline, between 5 and 15 amenorrhea weeks, between 15+1 day and 28+ 6 days amenorrhea weeks, between 29 and 44 amenorrhea weeks)
  • The rate of leptin (only dosage in fasting patients)(between 5 and 15 amenorrhea weeks)
  • The variation in oestradiol, testosterone and LH levels(At baseline, between 5 and 15 amenorrhea weeks, between 15+1 day and 28+ 6 days amenorrhea weeks, between 29 and 44 amenorrhea weeks)
  • The level of expression of aromatase, AMH and AMH Receptor II in the placenta(at delivery)

研究者

发起方
University Hospital, Lille
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验